KDM6A and chronic myelogenous leukemia, BCR-ABL1 positive: Numerous studies proved compelling evidence indicating that KDM6A in tumor cells not only contributes to tumorigenesis but also increases resistance to chemotherapy, such as imatinib treatment for chronic myelogenous leukemia (CML) (75–77).